Intestinal insulin releasing polypeptide (IRP) and Gastric inhibitory polypeptide (GIP) have a similar effect on intravenous glucose tolerance in the rat. Both augment the insulin response to intravenous glucose and increase the rate of glucose disappearance. VIP and motilin have no discernible effect. Plasma insulin doseresponse curves to IRP and GIP are similar; both peptides stimulate insulin release in the presence of small Mood glucose increments. A direct comparison of the insulin releasing potency of IRP and GIP is not possible as the former is not yet available in pure form.
A fraction from porcine duodenojejunal mucosa, intestinal insulin releasing polypeptide (IRP), has been prepared [1] and the suggestion made that it is responsible for the greater plasma insulin response to oral as compared to intravenous glucose. The possibility that the effects observed could be due to contamination of IRP by secretin, pancreozymin/cholecystokinin (CCK) or intestinal glucagon-like immunoreactivity (GLI) has been investigated and considered unlikely [2] on the evidence available. Three additionM intestinal polypeptides, vasoactive intestinal polypeptide (VIP) [3] , gastric inhibitory polypeptide (GIP) [4] and motilin [5] have recently been purified. All appear to be hormonally active and GIP has been shown to stimulate insulin release [6] . It was considered necessary, therefore, to investigate each of them to assess their ability to explain the observed effects of IRP on insulin secretion and their possible involvement in the intestinal regulation of insulin release.
Studies similar to those previously reported with IRP [1, 2] were performed using pure or partially pure preparations of GIP, VIP and motilin. In addition further studies were made of the conditions affecting IRP and GIP mediated insulin release in rats in vivo.
Materials and Methods
Intestinal insulin releasing polypeptide (IRP) was prepared by the method of Turner etal. [2] . A partially pure GIP preparation, containing approximately 40% GIP, and pure GIP were prepared by the method of Broml etal. [4] . Vasoactive intestinal polypeptide was prepared according to Said and Mutt [3] and motilin by the method of Brown et al. [5] . Insulin-free pork glucagon was given by Dr. Mary Root, Lilly Research Laboratories, Indianapolis, U.S.A. All solutions for injection contained gelatin, 0.05~o, as a carrier protein.
Overnight fasted twelve week old male Wistar rats weighing between 260 and 280 g were used for all experiments. Rats were anaesthetised by the intraperitoneal injection of sodium pentobarbitone, 40 mg/kg. Intravenous injections and blood sampling were carried out as previously described [2] . Blood glucose was measured by a glucose oxidase procedure [7] and plasma insulin by a double antibody radioimmunoassay [8] , using human insulin as standard.
Radioimmunoassay for GIP was performed on the IRP preparation used here by J. C.B. and by Dr. S.R. Bloom of the Middlesex Hospital, London. J.C.B. found an apparent GIP content of 1.2%, but the dilution slope of the cross reactivity was markedly different from that of GIP standards and other samples having excellent insulin releasing activity showed no detectable GIP content. Dr. S.R. Bloom found a content of 400 ng/mg. It is thus difficult to be certain of the nature or quantity of GIP immunoreactivity present in the IgP preparation.
Results

The Effect of Partially Pure GIP on Intravenous
Glucose Tolerance in the Rat The effect of partially pure GIP, injected intravenously at a dose of 5 ~g/kg, on the blood glucose and plasma insulin response to intravenous glucose is shown in Fig. i . The glucose disappearance rate in rats that received glucose plus GIP was faster than that in the rats receiving glucose alone and their mean blood glucose levels were significantly lower at 30 rain (p< 0.02) and 60 rain (p<0.05) after glucose injection. Mean plasma insulin levels in rats given GIP in addition to glucose were significantly higher at 5 rain (p< 0.01) and 10 min (/)<0.05) than in animals given glucose alone.
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Dose Response to Pure GIP
The curve obtained by plotting "glucose depend. ent" insulin releasing activity --expressed as a percentage of control values --against the dose of GIP is shown in Fig. 2 . Plasma insulin levels are given in Table 1 . The data represent mean plasma insulin levels observed in groups of eight rats, five minutes after the intravenous injection of glucose plus GIP, and in the figure are expressed as a percentage of the 5 min insulin level in control animals receiving glucose alone.
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-~ 15o Significant augmentation of insulin release (p< 0.01) was produced by 0.125 Fg/kg GIP. A dose of 1.0 Fg/kg GIP had a maximal insulin releasing effect. At a higher dose, 2.0 Fg/kg there was a suggestion of a reduction in effect. A plot of the mean 5 rain plasma insulin levels against log GIP dose is shown in Fig. 3 and demonstrates a log-linear relationship over much of the observed range. 
The Effect of Motilin and VIP on Insulin Release
The lack of effect upon glucose mediated insulin release of either VIP or motilin at various dose levels is shown in Fig. 2 and Table 1 . In consequence no further studies were made of these two peptides.
The Effect of Glucose Dosage on the Insulinaemic
Response to IRP a) A constant dose of IEP (0.5 mg/kg) was administered intravenously, simultaneously with differing quantities of glucose. Blood glucose and plasma insulin levels were measured 5 min after the injection. The results are shown in Fig. 4 . The injection of IRP plus glucose, 78 mg/kg, resulted in a 13 rag/100 ml increment in the mean 5 rain blood gincose level and was associated with a significant increase in plasma insulin level compared to animals given II~P in saline. The mean rise in plasma insulin was equal to that ordinarily associated with a rise in blood glucose of about 150 rag/ 100 ml produced by intravenous glucose alone. With increasing amounts of glucose added to the II~P a dose response curve for insulin release against blood glucose concentration was observed. This moved towards a plateau at blood glucose levels above 200 rag/100 ml. b) On this occasion the response to differen~ amounts of intravenous glucose in the presence or absence of II~P was investigated. The results are shown in Fig. 5 . Five minute plasma insulin levels were significantly higher at ~ll glucose dose levels in animals give IBP plus glucose than in those given glucose alone. IRP was not associated with any significant difference in 5 rain blood glucose levels at any glucose dose except the lowest. glucose alone. There were no differences in 5 rain blood glucose levels between the two groups. b) Because of differences between IRP and GIP treated animals in the 5 min blood glucose response to the lowest doses of glucose in experiments 4b and 5 a, further experiments were carried out to test the re- 
Glucose Dose and the Insulinaemic Response to GIP
a) The results of experiments similar to 4b, but in which pure GIP, 0.5 Fg/kg was substituted for IRP, are shown in Fig. 6 . The 5 min plasma insulin levels were significantly higher, at all glucose dosages, in animals receiving GIP plus glucose than in those given uation often observed during oral glucose tolerance tests in which a large rise in plasma insulin is associated with small increments in blood glucose concentration. Both GIP and II~P would seem to qualify, therefore, for consideration as the intestinal mediator of the augmented insulinaemic response to enteric glucose administration. It is clear that neither VIP nor motilin need be considered further, since, unlike II~P and GIP, neither polypeptide had a significant effect on glucose stimulated insulin release. A direct comparison of the insulin releasing potency of IEP and GIP was not possible due to the known, but unquantified, impurity of the IRP preparation currently available. The comparative data for glucagon used under the same conditions suggests that on a weight for weight basis GIP has an insulin releasing potency approximately four times that of glucagon, or in molar terms there is an approximately six fold difference in potency.
Our experiments revealed no essential difference between the insulin releasing effect of IEP and GIP. The question arises, therefore, as to whether the active component of the II~P preparation is GIP or an as yet uncharacterised polypeptide, and secondly whether GIP is normally involved in the insulin secretory response to oral glucose in man. A pointer to the possible non-identity of IRP and GIP comes from the observation that extracts of duodenum, a source of GIP, do not exhibit significant insulin releasing activity when prepared by methods used to produce IRP from the jejunum [9, 10] . The final answers to both questions must await further experiments, and ultimately the purification and chemical characterisation of the active component of IRP.
It is likely that GIP is closely related to, but not necessarily identical with, II~P, and that, as with other gastrointestinal polypeptides there is some sharing or overlapping of structure and biological activities.
